<p>Esperion Therapeutics, Inc.（纳斯达克代码：ESPR - 获取免费报告）的股票在覆盖该股票的八家研究公司中获得了 “适度买入” 的平均评级，MarketBeat 报道称。一位分析师给予该股票卖出评级，一位给予持有评级，五位给予买入评级，还有一位给予强烈买入评级。在过去一年中，覆盖该股票的经纪公司给出的平均一年目标价为 7.20 美元。</p>
<p>获取 <strong>Esperion Therapeutics</strong> 的提醒：</p>
<p>一些研究分析师最近对 ESPR 股票发表了评论。花旗集团在 11 月 12 日星期三的报告中重新发布了对 Esperion Therapeutics 股票的 “市场表现优于大盘” 评级。Cantor Fitzgerald 在 11 月 12 日星期三的研究报告中重申了对 Esperion Therapeutics 股票的 “增持” 评级。华尔街 Zen 在 11 月 1 日星期六的研究报告中将 Esperion Therapeutics 的评级从 “买入” 下调至 “持有”。HC Wainwright 在 9 月 19 日星期五的研究报告中重申了 “买入” 评级，并对 Esperion Therapeutics 股票设定了 16.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Esperion Therapeutics 股票的 “卖出（d-）” 评级。</p>
<p><strong>获取我们对 Esperion Therapeutics 的最新股票分析</strong></p>
<h2>Esperion Therapeutics 股票上涨 2.3%</h2>
<p>ESPR 的股票在周五以 4.04 美元开盘。Esperion Therapeutics 的 12 个月最低价为 0.69 美元，12 个月最高价为 4.13 美元。该公司的市值为 9.658 亿美元，市盈率为-8.08，贝塔值为 1.01。该公司的 50 日移动平均线为 3.34 美元，200 日移动平均线为 2.42 美元。</p>
<p>Esperion Therapeutics（纳斯达克代码：ESPR - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。这家生物制药公司报告的每股收益为（0.16 美元），低于分析师一致预期的（0.09 美元）7 美分。该公司本季度的收入为 8731 万美元，而一致预期为 7833 万美元。分析师预测 Esperion Therapeutics 在当前年度的每股收益为-0.29 美元。</p>
<h2>内部交易活动</h2>
<p>在其他消息中，首席财务官 Benjamin Halladay 在 12 月 17 日星期三的交易中出售了 7337 股该股票。股票以平均价格 3.67 美元出售，总交易额为 26926.79 美元。交易后，首席财务官持有 467525 股公司股票，价值约 1715816.75 美元。这笔交易代表了他们持有股票的 1.55% 的减少。该出售在向 SEC 提交的文件中披露，文件可通过此超链接访问。公司内部人士持有公司股票的 1.70%。</p>
<h2>Esperion Therapeutics 的机构交易</h2>
<p>机构投资者和对冲基金最近买卖了该公司的股票。制造商人寿保险公司在第二季度增持了 Esperion Therapeutics 的股份，增幅为 7.4%。制造商人寿保险公司现在拥有 72705 股生物制药公司的股票，价值 72000 美元，此前在上个季度又购买了 4979 股。CWM LLC 在第三季度增持了 Esperion Therapeutics 的股份，增幅为 46.5%。CWM LLC 现在拥有 19674 股生物制药公司的股票，价值 52000 美元，此前在上个季度又购买了 6249 股。DHJJ Financial Advisors Ltd.在第三季度增持了 Esperion Therapeutics 的股份，增幅为 209.2%。DHJJ Financial Advisors Ltd.现在拥有 9430 股生物制药公司的股票，价值 25000 美元，此前在上个季度又购买了 6380 股。Wealth Enhancement Advisory Services LLC 在第三季度增持了 Esperion Therapeutics 的股份，增幅为 54.1%。Wealth Enhancement Advisory Services LLC 现在拥有 23916 股生物制药公司的股票，价值 63000 美元，此前在该期间又购买了 8394 股。最后，North Star Investment Management Corp.在第三季度增持了 Esperion Therapeutics 的股份，增幅为 40.0%。North Star Investment Management Corp.现在拥有 35000 股生物制药公司的股票，价值 93000 美元，此前在上个季度又购买了 10000 股。机构投资者和对冲基金持有公司股票的 47.39%。</p>
<h2>关于 Esperion Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Esperion Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于口服低密度脂蛋白胆固醇（LDL-C）降低疗法的发现、开发和商业化。该公司的研发工作集中在小分子化合物上，旨在通过靶向胆固醇生物合成途径来应对动脉粥样硬化性心血管疾病。Esperion 旨在为需要额外 LDL-C 降低的患者提供新型治疗选择，这些患者在使用他汀类药物后仍需进一步降低，或对他汀类药物不耐受。</p>
<p>该公司的主要产品包括 NEXLETOL（苯佩多酸），这是一种已获得美国批准的口服腺苷三磷酸 - 柠檬酸裂解酶（ACL）抑制剂。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Esperion Therapeutics</li>
<li>华尔街选股者评选 2026 年第一只股票</li>
<li>[紧急！] SpaceX 即将上市！- IPO 前行动</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>开火正式开始……</li>
<li>距离崩盘还有一个月</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVNQUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVNQUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Esperion Therapeutics 吗？</h2>
<p>在考虑 Esperion Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Esperion Therapeutics 并不在名单上。</p>
<p>虽然 Esperion Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ESPR

<p>Esperion Therapeutics, Inc.（纳斯达克代码：ESPR）获得了八家研究公司的平均 “适度买入” 评级。分析师设定的平均一年价格目标为 7.20 美元。该股票开盘价为 4.04 美元，12 个月的价格区间为 0.69 美元至 4.13 美元。最近的内部交易包括首席财务官本杰明·哈拉迪出售股份。机构投资者持有该股票的 47.39%。Esperion 专注于降低 LDL-C 的疗法，其主要产品 NEXLETOL 已在美国获得批准</p>

<p>Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have earned an average rating of &#34;Moderate Buy&#34; from the eight research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $7.20.</p>
<div class="lb-trans"><p>Esperion Therapeutics, Inc.（纳斯达克代码：ESPR - 获取免费报告）的股票在覆盖该股票的八家研究公司中获得了 “适度买入” 的平均评级，MarketBeat 报道称。一位分析师给予该股票卖出评级，一位给予持有评级，五位给予买入评级，还有一位给予强烈买入评级。在过去一年中，覆盖该股票的经纪公司给出的平均一年目标价为 7.20 美元。</p>
</div><p>Get <strong>Esperion Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Esperion Therapeutics</strong> 的提醒：</p>
</div><p>A number of research analysts recently commented on ESPR shares. Citigroup reissued a &#34;market outperform&#34; rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Wall Street Zen cut Esperion Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 1st. HC Wainwright restated a &#34;buy&#34; rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Friday, September 19th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>一些研究分析师最近对 ESPR 股票发表了评论。花旗集团在 11 月 12 日星期三的报告中重新发布了对 Esperion Therapeutics 股票的 “市场表现优于大盘” 评级。Cantor Fitzgerald 在 11 月 12 日星期三的研究报告中重申了对 Esperion Therapeutics 股票的 “增持” 评级。华尔街 Zen 在 11 月 1 日星期六的研究报告中将 Esperion Therapeutics 的评级从 “买入” 下调至 “持有”。HC Wainwright 在 9 月 19 日星期五的研究报告中重申了 “买入” 评级，并对 Esperion Therapeutics 股票设定了 16.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 Esperion Therapeutics 股票的 “卖出（d-）” 评级。</p>
</div><p><strong>Get Our Latest Stock Analysis on Esperion Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Esperion Therapeutics 的最新股票分析</strong></p>
</div><h2>Esperion Therapeutics Trading Up 2.3%</h2>
<div class="lb-trans"><h2>Esperion Therapeutics 股票上涨 2.3%</h2>
</div><p>Shares of ESPR opened at $4.04 on Friday. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $4.13. The firm has a market capitalization of $965.80 million, a P/E ratio of -8.08 and a beta of 1.01. The firm's 50-day moving average is $3.34 and its two-hundred day moving average is $2.42.</p>
<div class="lb-trans"><p>ESPR 的股票在周五以 4.04 美元开盘。Esperion Therapeutics 的 12 个月最低价为 0.69 美元，12 个月最高价为 4.13 美元。该公司的市值为 9.658 亿美元，市盈率为-8.08，贝塔值为 1.01。该公司的 50 日移动平均线为 3.34 美元，200 日移动平均线为 2.42 美元。</p>
</div><p>Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.07). The business had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million. Analysts predict that Esperion Therapeutics will post -0.29 EPS for the current year.</p>
<div class="lb-trans"><p>Esperion Therapeutics（纳斯达克代码：ESPR - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。这家生物制药公司报告的每股收益为（0.16 美元），低于分析师一致预期的（0.09 美元）7 美分。该公司本季度的收入为 8731 万美元，而一致预期为 7833 万美元。分析师预测 Esperion Therapeutics 在当前年度的每股收益为-0.29 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the transaction, the chief financial officer owned 467,525 shares of the company's stock, valued at approximately $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Benjamin Halladay 在 12 月 17 日星期三的交易中出售了 7337 股该股票。股票以平均价格 3.67 美元出售，总交易额为 26926.79 美元。交易后，首席财务官持有 467525 股公司股票，价值约 1715816.75 美元。这笔交易代表了他们持有股票的 1.55% 的减少。该出售在向 SEC 提交的文件中披露，文件可通过此超链接访问。公司内部人士持有公司股票的 1.70%。</p>
</div><h2>Institutional Trading of Esperion Therapeutics</h2>
<div class="lb-trans"><h2>Esperion Therapeutics 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its holdings in Esperion Therapeutics by 7.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company's stock worth $72,000 after buying an additional 4,979 shares during the last quarter. CWM LLC lifted its stake in Esperion Therapeutics by 46.5% during the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company's stock worth $52,000 after purchasing an additional 6,249 shares during the last quarter. DHJJ Financial Advisors Ltd. lifted its stake in Esperion Therapeutics by 209.2% during the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 6,380 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Esperion Therapeutics by 54.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 23,916 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 8,394 shares during the period. Finally, North Star Investment Management Corp. increased its stake in Esperion Therapeutics by 40.0% during the third quarter. North Star Investment Management Corp. now owns 35,000 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该公司的股票。制造商人寿保险公司在第二季度增持了 Esperion Therapeutics 的股份，增幅为 7.4%。制造商人寿保险公司现在拥有 72705 股生物制药公司的股票，价值 72000 美元，此前在上个季度又购买了 4979 股。CWM LLC 在第三季度增持了 Esperion Therapeutics 的股份，增幅为 46.5%。CWM LLC 现在拥有 19674 股生物制药公司的股票，价值 52000 美元，此前在上个季度又购买了 6249 股。DHJJ Financial Advisors Ltd.在第三季度增持了 Esperion Therapeutics 的股份，增幅为 209.2%。DHJJ Financial Advisors Ltd.现在拥有 9430 股生物制药公司的股票，价值 25000 美元，此前在上个季度又购买了 6380 股。Wealth Enhancement Advisory Services LLC 在第三季度增持了 Esperion Therapeutics 的股份，增幅为 54.1%。Wealth Enhancement Advisory Services LLC 现在拥有 23916 股生物制药公司的股票，价值 63000 美元，此前在该期间又购买了 8394 股。最后，North Star Investment Management Corp.在第三季度增持了 Esperion Therapeutics 的股份，增幅为 40.0%。North Star Investment Management Corp.现在拥有 35000 股生物制药公司的股票，价值 93000 美元，此前在上个季度又购买了 10000 股。机构投资者和对冲基金持有公司股票的 47.39%。</p>
</div><h2>About Esperion Therapeutics</h2>
<div class="lb-trans"><h2>关于 Esperion Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.</p>
<div class="lb-trans"><p>Esperion Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于口服低密度脂蛋白胆固醇（LDL-C）降低疗法的发现、开发和商业化。该公司的研发工作集中在小分子化合物上，旨在通过靶向胆固醇生物合成途径来应对动脉粥样硬化性心血管疾病。Esperion 旨在为需要额外 LDL-C 降低的患者提供新型治疗选择，这些患者在使用他汀类药物后仍需进一步降低，或对他汀类药物不耐受。</p>
</div><p>The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.</p>
<div class="lb-trans"><p>该公司的主要产品包括 NEXLETOL（苯佩多酸），这是一种已获得美国批准的口服腺苷三磷酸 - 柠檬酸裂解酶（ACL）抑制剂。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Esperion Therapeutics</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>[URGENT!] SpaceX Going Public! – Pre-IPO Action</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Shots officially fired…</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Esperion Therapeutics</li>
<li>华尔街选股者评选 2026 年第一只股票</li>
<li>[紧急！] SpaceX 即将上市！- IPO 前行动</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>开火正式开始……</li>
<li>距离崩盘还有一个月</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVNQUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ESPR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Esperion Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Esperion Therapeutics 吗？</h2>
</div><p>Before you consider Esperion Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Esperion Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Esperion Therapeutics 并不在名单上。</p>
</div><p>While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Esperion Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Esperion Therapeutics, Inc. (NASDAQ:ESPR) 获得券商的平均推荐评级为 “适度买入”